Product Development

Substantial proof of concept data exists from academic studies to show the potential of BETA both ex vivo and in vivo (see ‘Publications’). Ablatus Therapeutics is now developing BETA as a medical device for use in initial clinical studies, ultimately leading to a CE-mark and market launch.

The Company’s development plans are underpinned by a grant from Innovate UK, awarded in 2017. In conjunction with our consortium partners, eg Technology, we are developing and testing a complete BETA system, to the appropriate regulatory requirements, to enable first time in man studies to commence in 2019.